GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment

GlaxoSmithkline est le 2e groupe pharmaceutique mondial. 
- produits pharmaceutiques. Les médicaments mis au point par le groupe correspondent essentiellement à 6 types de traitements : dysfonctionnement du système nerveux, maladies respiratoires (le groupe produit notamment la Ventoline), dysfonctionnement du système immunitaire , anti-viraux , maladies gastro-intestinales , vaccins , oncologie , maladies cardio-vasculaires  et autres
- médicaments OTC et para-pharmacie . GlaxoSmithkline détient également une position dominante dans le domaine de l'automédication (analgésiques, traitement des maladies gastro-intestinales...) et des produits para-pharmaceutiques (dermatologie, soins dentaires, vitamines, diététique...)

Q1 2006 SUMMARY*
Total pharmaceutical sales grew 10% to £5 billion, driven by 15% growth in the USA.
Key growth drivers performed strongly with sales totalling £2.2 billion (+22%):

Seretide/Advair (+12% to £816 million)
Avandia products (+24% to £384 million)
Vaccines (+44% to £366 million)
Lamictal (+14% to £237 million)
Coreg (+53% to £225 million)
Valtrex (+16% to £204 million)
Excellent first quarter financial performance with EPS growth of 17% (26% reported).
Significant progress on important near-term pipeline opportunities:
Cervarix (vaccine for the prevention of cervical cancer) was filed in the EU and in 13 International markets in March.  Latest data (4.5 years) shows 100% sustained efficacy against pre-cancerous lesions caused by HPV 16 and 18.
Excellent phase III efficacy data for Tykerb (a new oral medicine for breast cancer) were received in April and will support an earlier filing date of H2 2006 in Europe and the USA.
Positive phase III data for Trexima (a new treatment for migraine to be launched later this year) were presented in April demonstrating superiority over current ‘gold standard’ Imitrex.
4 products started phase III/registration trials so far this year:
Eltrombopag for low blood platelets, pazopanib for cancer, casopitant for nausea and vomiting and H5N1 vaccine for flu pandemic.
GSK continues to expect 2006 earnings per share growth to be around 10% in CER terms.

Preliminary Announcement of Results for the year ended 31st December 2005 Q4 Results Announcement 2005 PDF
Excellent 2005 performance for GSK
Full Year EPS up 18% CER (21% reported); Q4 EPS up 33% CER (47% reported)
GlaxoSmithKline plc (GSK) today announces its results for the year ended 31st December 2005.
The full results, which have been prepared under IFRS, are presented under ‘Income Statement’ on pages 7 and 8, and are summarised below.
SUMMARY*
Excellent 2005 financial performance:
EPS growth of 18% CER to 82.6p, with growth in Q4 of 33% CER to 19.8p
2005 dividend of 44p
Key growth products drive 2005 pharma turnover +8% to £18.7 billion:
Seretide/Advair sales exceed £3 billion, up 22%
Avandia/Avandamet for diabetes +18% to £1.3 billion
Vaccines +15% to £1.4 billion
Significant pipeline progress:
7 products to be approved/launched during 2006
7 product filings planned for 2006.  Cervarix expected to be filed in the EU in March 2006 and in the USA before the end of 2006
Late-stage pipeline continues to expand with 8 major assets expected to enter phase III development during 2006
Financial outlook:
2006 earnings per share growth expected to be around 10% in CER terms